While gastrointestinal issues are the most common side effects, a recent study by the University of British Columbia linked ...

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as ...

President Trump has announced sweeping tariffs on several countries. Novo Nordisk and Smith & Nephew may be the most at risk ...

Here's everything you need to know about the new weight loss medication being rolled out by the NHS to treat obesity.

Artisan Partners, an investment management company, released its “Artisan Global Opportunities Fund” fourth quarter 2024 ...

Hims & Hers (HIMS) stock slid Wednesday, a day after the company announced new weight-loss drug offerings — an update that left investors unimpressed.

The telehealth company is offering Lilly’s branded form of tirzepatide—approved for weight loss—on its site for $1,899 a ...

Telehealth platform Hims & Hers Health, Inc. (HIMS), which connects consumers to healthcare professionals, is at a crossroads ...

President Donald Trump is expected to announce sweeping tariffs on “all countries" affecting many industries, the likes of ...

Trump’s tariffs on EU goods could slash exports by at least €85 billion, hitting autos and pharmaceuticals hardest. Germany, ...